Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation
Florian A. Lempp, Franziska Schlund, Lisa Rieble, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Stephan Urban, Christoph Neumann‐Haefelin, Pietro Lampertico
Gut (2021) Vol. 70, Iss. 9, pp. 1782-1794
Open Access | Times Cited: 174
A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis
Cihan Yurdaydìn, Onur Keskın, Esra Yurdcu, et al.
Hepatology (2021) Vol. 75, Iss. 6, pp. 1551-1565
Closed Access | Times Cited: 59
Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread
Zhenfeng Zhang, Yi Ni, Florian A. Lempp, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 957-966
Closed Access | Times Cited: 49
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
Sheli R. Radoshitzky, Patrick L. Iversen, Xianghan Lu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 33
New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies
Zhenfeng Zhang, Stephan Urban
Journal of Hepatology (2020) Vol. 74, Iss. 3, pp. 686-699
Open Access | Times Cited: 50
Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates
Wenshi Wang, Florian A. Lempp, Franziska Schlund, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 2, pp. 311-323
Open Access | Times Cited: 43
Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection
Toni Herta, Magdalena Hahn, Melanie Maier, et al.
Pathogens (2022) Vol. 11, Iss. 5, pp. 517-517
Open Access | Times Cited: 28
CRISPR/Cas13a-Assisted accurate and portable hepatitis D virus RNA detection
Yuan Tian, Zihao Fan, Xiangying Zhang, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 18
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
Vincent Soriano, Víctor Moreno‐Torres, Ana Treviño, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 155-166
Open Access | Times Cited: 15
Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus
Yi Ni, Zhenfeng Zhang, Lisa Engelskircher, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 27
Interplay between Hepatitis D Virus and the Interferon Response
Zhenfeng Zhang, Stephan Urban
Viruses (2020) Vol. 12, Iss. 11, pp. 1334-1334
Open Access | Times Cited: 25
HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection
Imme Roggenbach, Xiumei Chi, Florian A. Lempp, et al.
Viruses (2021) Vol. 13, Iss. 9, pp. 1799-1799
Open Access | Times Cited: 23
Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method
Éloi R. Verrier, Anna Salvetti, Caroline Pons, et al.
Antiviral Research (2022) Vol. 198, pp. 105250-105250
Open Access | Times Cited: 13
In vitro cell culture models to study hepatitis B and D virus infection
Hongbo Guo, Stephan Urban, Wenshi Wang
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 7
HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression
Matthieu Blanchet, Léna Angelo, Yasmine Tétreault, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 532-532
Open Access | Times Cited: 2
Cell Culture Models for Hepatitis B and D Viruses Infection: Old Challenges, New Developments and Future Strategies
Arnaud Carpentier
Viruses (2024) Vol. 16, Iss. 5, pp. 716-716
Open Access | Times Cited: 2
The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA
Shirin Nkongolo, Lea Nußbaum, Florian A. Lempp, et al.
Antiviral Research (2019) Vol. 168, pp. 146-155
Open Access | Times Cited: 18
Combination of Novel Therapies for HDV
Menashe Elazar, Jeffrey S. Glenn
Viruses (2022) Vol. 14, Iss. 2, pp. 268-268
Open Access | Times Cited: 10
Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes
Frauke Lange, Jonathan Garn, Holda A. Anagho, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2116-2129
Open Access | Times Cited: 6
JAK1 promotes HDV replication and is a potential target for antiviral therapy
Margaux J. Heuschkel, C Bach, Laura Meiss-Heydmann, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 220-231
Open Access | Times Cited: 6
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations
Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, et al.
JHEP Reports (2023) Vol. 6, Iss. 2, pp. 100966-100966
Open Access | Times Cited: 6
Dual role of neddylation in transcription of hepatitis B virus RNAs from cccDNA and production of viral surface antigen
Bingqian Qu, Firat Nebioglu, Mila M. Leuthold, et al.
JHEP Reports (2022) Vol. 4, Iss. 10, pp. 100551-100551
Open Access | Times Cited: 9
Hepatitis delta: Epidemiology to recent advances in therapeutic agents
Nehna Abdul Majeed, Benno Zehnder, Christopher Koh, et al.
Hepatology (2023) Vol. 78, Iss. 4, pp. 1306-1321
Closed Access | Times Cited: 4
Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity
Armando Andres Roca Suarez, Enkhtuul Batbold, Birke Bartosch, et al.
Liver International (2023) Vol. 43, Iss. S1, pp. 87-95
Closed Access | Times Cited: 4
Cellular Factors Involved in the Hepatitis D Virus Life Cycle
Keerthihan Thiyagarajah, Michael Basic, Eberhard Hildt
Viruses (2023) Vol. 15, Iss. 8, pp. 1687-1687
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top